AMGNAmgenRunning, no new patients
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Advanced MTAP-null Solid Tumors
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 329 (final count)
- Started
- Feb 1, 2022
- Main results expected
- Nov 30, 2026
- Fully finished
- Nov 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
Measured over: 28 days
Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
Measured over: Up to approximately 3 years
Part 3: Objective Response Rate (ORR)
Measured over: Up to approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05094336 · record last updated 2026-05-28 · checked 2026-11-09 15:47 UTC